Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
J Integr Neurosci ; 23(2): 39, 2024 Feb 19.
Artigo em Inglês | MEDLINE | ID: mdl-38419446

RESUMO

BACKGROUND: Medium-chain triglycerides such as decanoic acid (C10), which is one of the fatty acids that constitute dietary fats, are of substantial interest for their potential therapeutic effects on neuropsychiatric disorders. However, the effects of C10 on attention-deficit/hyperactivity disorder (ADHD) remain to be studied. We explored the effects of C10 on behavioural activity and antioxidant defences in an experimental animal model of ADHD. METHODS: To establish an experimental animal model of ADHD, neonatal rats were subjected to unilateral striatal lesions using 6-hydroxydopamine (6-OHDA). The rats sequentially underwent open-field and Y-maze tests before treatment [postnatal day 25 (PN25)]. After the subcutaneous administration of either vehicle or C10 solution (250 mg/kg) for 14 days, the behavioural tests were repeated on PN39. Next, we examined the effects of C10 on the expression of the constitutive antioxidant enzymes catalase and glutathione peroxidase-1/2 and the phase II transcription factor nuclear factor erythroid 2-related factor 2 in four different regions of the rat brain. RESULTS: Injection of 6-OHDA unilaterally into the striatum resulted in elevated locomotor activity on PN39. The administration of C10 for a period of 14 days did not alter the locomotor hyperactivity. Moreover, the administration of C10 had no significant effects on the expression of proteins related to antioxidant defences in the hippocampus, prefrontal cortex, striatum or cerebellum of both control and lesioned rats. CONCLUSIONS: The lack of significant effects of C10 in our study may depend on the dose and duration of C10 administration. Further exhaustive studies are needed to verify the efficacy and effects of different doses and treatment durations of C10 and to explore the underlying mechanisms.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Ratos , Animais , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Oxidopamina/farmacologia , Antioxidantes/farmacologia , Modelos Animais de Doenças , Locomoção , Ácidos Decanoicos/uso terapêutico
2.
J Clin Neurosci ; 74: 187-193, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32169363

RESUMO

High grade gliomas are associated with poor prognosis and high mortality. Conventional treatments and management of high grade gliomas have shown little improvement in 5-year overall survival. This phase I trial evaluated the safety, immunogenicity, and potential synergy of surgical resection with Gliadel Wafer implantation, followed by autologous tumor lysate-pulsed dendritic cell (DC) vaccine in patients with malignant glioma. Primary end points of this study were safety and surrogate markers of immunogenicity, overall survival, and progression free survival. Following surgical resection, Gliadel Wafers were placed along the resection cavity. Patients subsequently received intradermal injections of autologous tumor lysate-pulsed DC vaccines 3 times at 2 week intervals. Treatment response was evaluated clinically and through MRI at regular intervals. Twenty-eight patients received Gliadel Wafers and DC vaccination: 11 newly diagnosed (8 glioblastoma [GBM], 2 anaplastic astrocytoma [AA], and 1 anaplastic oligodendroglioma [AO]) and 17 recurrent (15 GBMs, 1 AA, and 1 AO) high grade gliomas. Immunogenicity data was collected for 20 of the 28 patients. Five of 20 patients showed elevated IFN-γ responses following vaccination. Median progression-free survival and overall survival for all GBM patients in the trial from the start of vaccination were 3.6 months and 16.9 months respectively. Comparisons between vaccine responders and non-vaccine responders were not statistically significant. Adjuvant autologous dendritic cells pulsed with tumor-lysate following resection and Gliadel Wafer placement is safe, elicits modest immunogenicity and shows similar clinical outcomes in patients who had DC vaccination in previous studies.


Assuntos
Neoplasias Encefálicas/terapia , Vacinas Anticâncer/uso terapêutico , Carmustina/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Células Dendríticas/transplante , Glioma/terapia , Poliésteres/uso terapêutico , Adulto , Idoso , Antígenos de Neoplasias/imunologia , Antineoplásicos/uso terapêutico , Terapia Combinada/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Vacinação/métodos
3.
Sci Rep ; 9(1): 14926, 2019 10 17.
Artigo em Inglês | MEDLINE | ID: mdl-31624310

RESUMO

Deep eutectic solvents have been recently reported as an interesting alternative to improve the therapeutic efficacy of conventional drugs, hence called therapeutic deep eutectic solvents (THEDES). The main objective of this work was to evaluate the potential of limonene (LIM) based THEDES as new possible systems for cancer treatment. LIM is known to have antitumor activity, however it is highly toxic and cell viability is often compromised, thus this compound is not selective towards cancer cells. Different THEDES based on LIM were developed to unravel the anticancer potential of such systems. THEDES were prepared by gently mixing saturated fatty acids menthol or ibuprofen (IBU) with LIM. Successful THEDES were obtained for Menthol:LIM (1:1), CA:LIM (1:1), IBU:LIM (1:4) and IBU:LIM(1:8). The results indicate that all the THEDES present antiproliferative properties, but IBU:LIM (1:4) was the only formulation able to inhibit HT29 proliferation without comprising cell viability. Therefore, IBU:LIM (1:4) was the formulation selected for further assessment of anticancer properties. The results suggest that the mechanism of action of LIM:IBU (1:4) is different from isolated IBU and LIM, which suggest the synergetic effect of DES. In this work, we unravel a methodology to tune the selectivity of LIM towards HT29 cell line without compromising cell viability of healthy cells. We demonstrate furthermore that coupling LIM with IBU leads also to an enhancement of the anti-inflammatory activity of IBU, which may be important in anti-cancer therapies.


Assuntos
Antineoplásicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Líquidos Iônicos/farmacologia , Limoneno/farmacologia , Neoplasias/tratamento farmacológico , Antineoplásicos/química , Antineoplásicos/uso terapêutico , Células CACO-2 , Sobrevivência Celular/efeitos dos fármacos , Ácidos Decanoicos/química , Ácidos Decanoicos/farmacologia , Ácidos Decanoicos/uso terapêutico , Composição de Medicamentos/métodos , Ensaios de Seleção de Medicamentos Antitumorais , Células HT29 , Humanos , Ibuprofeno/química , Ibuprofeno/farmacologia , Ibuprofeno/uso terapêutico , Líquidos Iônicos/química , Líquidos Iônicos/uso terapêutico , Limoneno/química , Limoneno/uso terapêutico , Mentol/química , Mentol/farmacologia , Mentol/uso terapêutico , Ácido Mirístico/química , Ácido Mirístico/farmacologia , Ácido Mirístico/uso terapêutico , Neoplasias/patologia
4.
J Control Release ; 295: 93-101, 2019 02 10.
Artigo em Inglês | MEDLINE | ID: mdl-30605703

RESUMO

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals living long term (p < .0038 vs. Control; p < .001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.


Assuntos
Antineoplásicos Alquilantes/administração & dosagem , Neoplasias Encefálicas/tratamento farmacológico , Carmustina/administração & dosagem , Ácidos Decanoicos/administração & dosagem , Preparações de Ação Retardada/química , Glioblastoma/tratamento farmacológico , Poliésteres/administração & dosagem , Temozolomida/administração & dosagem , Animais , Antineoplásicos Alquilantes/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carmustina/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Implantes de Medicamento/química , Feminino , Poliésteres/uso terapêutico , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química , Ratos Endogâmicos F344 , Temozolomida/uso terapêutico
6.
Bull Exp Biol Med ; 163(1): 22-24, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28577088

RESUMO

The role of KATP channels in myocardial infarct size-limiting effect of chronic continuous normobaric hypoxia was examined in a rat model based on a 20-min coronary occlusion and subsequent 3-h reperfusion. Rats were adapted to normobaric hypoxia (12% O2) for 21 days. This hypoxia produced a pronounced infarct size-limiting effect, which had been prevented by 0.3 mg/kg glibenclamide, a non-selective inhibitor of entire pool of KATP channels, or 5 mg/kg 5-hydroxydecanoate, an inhibitor of mitochondrial KATP channels. The study highlighted the important role of mitochondrial KATP channels in myocardial infarct size-limiting effect of chronic normobaric hypoxia.


Assuntos
Hipóxia/fisiopatologia , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/fisiopatologia , Traumatismo por Reperfusão Miocárdica/metabolismo , Traumatismo por Reperfusão Miocárdica/fisiopatologia , Canais de Potássio/metabolismo , Animais , Pressão Sanguínea/efeitos dos fármacos , Ácidos Decanoicos/uso terapêutico , Glibureto/uso terapêutico , Frequência Cardíaca/efeitos dos fármacos , Hidroxiácidos/uso terapêutico , Masculino , Infarto do Miocárdio/tratamento farmacológico , Bloqueadores dos Canais de Potássio/uso terapêutico , Ratos , Ratos Wistar
7.
Curr Opin Neurol ; 30(2): 187-192, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28141738

RESUMO

PURPOSE OF REVIEW: High-fat, low-carbohydrate ketogenic diets have been used for almost a century for the treatment of epilepsy. Used traditionally for the treatment of refractory pediatric epilepsies, in recent years the use of ketogenic diets has experienced a revival to include the treatment of adulthood epilepsies as well as conditions ranging from autism to chronic pain and cancer. Despite the ability of ketogenic diet therapy to suppress seizures refractory to antiepileptic drugs and reports of lasting seizure freedom, the underlying mechanisms are poorly understood. This review explores new insights into mechanisms mobilized by ketogenic diet therapies. RECENT FINDINGS: Ketogenic diets act through a combination of mechanisms, which are linked to the effects of ketones and glucose restriction, and to interactions with receptors, channels, and metabolic enzymes. Decanoic acid, a component of medium-chain triclycerides, contributes to seizure control through direct α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition, whereas drugs targeting lactate dehydrogenase reduce seizures through inhibition of a metabolic pathway. Ketogenic diet therapy also affects DNA methylation, a novel epigenetic mechanism of the diet. SUMMARY: Ketogenic diet therapy combines several beneficial mechanisms that provide broad benefits for the treatment of epilepsy with the potential to not only suppress seizures but also to modify the course of the epilepsy.


Assuntos
Dieta Cetogênica , Anticonvulsivantes/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Epilepsia/tratamento farmacológico , Humanos , Convulsões/tratamento farmacológico
8.
World J Surg Oncol ; 14(1): 225, 2016 Aug 24.
Artigo em Inglês | MEDLINE | ID: mdl-27557526

RESUMO

Since 2003, only two chemotherapeutic agents, evaluated in phase III trials, have been approved by the US Food and Drug Administration for treatment of newly diagnosed high-grade glioma (HGG): Gliadel wafers (intracranially implanted local chemotherapy) and temozolomide (TMZ) (systemic chemotherapy). Neither agent is curative, but each has been shown to improve median overall survival (OS) compared to radiotherapy (RT) alone. To date, no phase III trial has tested these agents when used in sequential combination; however, a number of smaller trials have reported favorable results. We performed a systematic literature review to evaluate the combination of Gliadel wafers with standard RT (60 Gy) plus concurrent and adjuvant TMZ (RT/TMZ) for newly diagnosed HGG. A literature search was conducted for the period of January 1995 to September 2015. Data were extracted and categorized, and means and ranges were determined. A total of 11 publications met criteria, three prospective trials and eight retrospective studies, representing 411 patients who received Gliadel plus standard RT/TMZ. Patients were similar in age, gender, and performance status. The weighted mean of median OS was 18.2 months (ten trials, n = 379, range 12.7 to 21.3 months), and the weighted mean of median progression-free survival was 9.7 months (seven trials, n = 287, range 7 to 12.9 months). The most commonly reported grade 3 and 4 adverse events were myelosuppression (10.22 %), neurologic deficit (7.8 %), and healing abnormalities (4.3 %). Adverse events reflected the distinct independent safety profiles of Gliadel wafers and RT/TMZ, with little evidence of enhanced toxicity from their use in sequential combination. In the 11 identified trials, an increased benefit from sequentially combining Gliadel wafers with RT/TMZ was strongly suggested. Median OS tended to be improved by 3 to 4 months beyond that observed for Gliadel wafers or TMZ when used alone in the respective phase III trials. Larger prospective trials of Gliadel plus RT/TMZ are warranted.


Assuntos
Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/terapia , Carmustina/uso terapêutico , Dacarbazina/análogos & derivados , Ácidos Decanoicos/uso terapêutico , Glioblastoma/patologia , Glioblastoma/terapia , Poliésteres/uso terapêutico , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/efeitos adversos , Antineoplásicos Alquilantes/uso terapêutico , Neoplasias Encefálicas/mortalidade , Carmustina/administração & dosagem , Carmustina/efeitos adversos , Quimiorradioterapia , Quimioterapia Adjuvante , Ensaios Clínicos Fase III como Assunto , Terapia Combinada/métodos , Dacarbazina/administração & dosagem , Dacarbazina/efeitos adversos , Dacarbazina/uso terapêutico , Ácidos Decanoicos/administração & dosagem , Ácidos Decanoicos/efeitos adversos , Intervalo Livre de Doença , Implantes de Medicamento , Glioblastoma/mortalidade , Humanos , Pessoa de Meia-Idade , Gradação de Tumores , Poliésteres/administração & dosagem , Poliésteres/efeitos adversos , Temozolomida , Estados Unidos , United States Food and Drug Administration
9.
Artigo em Inglês | MEDLINE | ID: mdl-27118251

RESUMO

Basic science studies have advanced our understanding of the role of key enzymes in the steroidogenesis pathway and those that affect the pathophysiology of PCOS. Studies with ovarian theca cells taken from women with PCOS have demonstrated increased androgen production due to increased CYP17A1 and HSD3B2 enzyme activities. Furthermore, overexpression of DENND1A variant 2 in normal theca cells resulted in a PCOS phenotype with increased androgen production. Notably, cellular steroidogenesis models have facilitated the understanding of the mechanistic effects of pharmacotherapies, including insulin sensitizers (e.g., pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production. In addition, animal models of PCOS have provided a critical platform to study the effects of therapeutic agents in a manner closer to the physiological state. Indeed, recent breakthroughs have demonstrated that natural derivatives such as the dietary medium-chain fatty acid decanoic acid (DA) can restore estrous cyclicity and lower androgen levels in an animal model of PCOS, thus laying the platform for novel therapeutic developments in PCOS. This chapter reviews the current understanding on the pathways modulating androgen biosynthesis, and the cellular and animal models that form the basis for preclinical research in PCOS, and sets the stage for clinical research.


Assuntos
Androgênios/biossíntese , Hiperandrogenismo/metabolismo , Síndrome do Ovário Policístico/metabolismo , Células Tecais/metabolismo , Animais , Proteínas Adaptadoras de Sinalização de Receptores de Domínio de Morte/metabolismo , Ácidos Decanoicos/uso terapêutico , Modelos Animais de Doenças , Feminino , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Humanos , Hiperandrogenismo/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Técnicas In Vitro , Resistência à Insulina , Metformina/uso terapêutico , Pioglitazona , Síndrome do Ovário Policístico/tratamento farmacológico , Progesterona Redutase/metabolismo , Esteroide 17-alfa-Hidroxilase/metabolismo , Tiazolidinedionas/uso terapêutico
11.
Endocrinology ; 157(1): 382-94, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26465200

RESUMO

Hyperandrogenism is the central feature of polycystic ovary syndrome (PCOS). Due to the intricate relationship between hyperandrogenism and insulin resistance in PCOS, 50%-70% of these patients also present with hyperinsulinemia. Metformin, an insulin sensitizer, has been used to reduce insulin resistance and improve fertility in women with PCOS. In previous work, we have noted that a dietary medium-chain fatty acid, decanoic acid (DA), improves glucose tolerance and lipid profile in a mouse model of diabetes. Here, we report for the first time that DA, like metformin, inhibits androgen biosynthesis in NCI-H295R steroidogenic cells by regulating the enzyme 3ß-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase type 2 (HSD3B2). The inhibitory effect on HSD3B2 and androgen production required cAMP stimulation, suggesting a mechanistic action via the cAMP-stimulated pathway. Specifically, both DA and metformin reduced cAMP-enhanced recruitment of the orphan nuclear receptor Nur77 to the HSD3B2 promoter, coupled with decreased transcription and protein expression of HSD3B2. In a letrozole-induced PCOS rat model, treatment with DA or metformin reduced serum-free testosterone, lowered fasting insulin, and restored estrous cyclicity. In addition, DA treatment lowered serum total testosterone and decreased HSD3B2 protein expression in the adrenals and ovaries. We conclude that DA inhibits androgen biosynthesis via mechanisms resulting in the suppression of HSD3B2 expression, an effect consistently observed both in vitro and in vivo. The efficacy of DA in reversing the endocrine and metabolic abnormalities of the letrozole-induced PCOS rat model are promising, raising the possibility that diets including DA could be beneficial for the management of both hyperandrogenism and insulin resistance in PCOS.


Assuntos
Ácidos Decanoicos/uso terapêutico , Gorduras na Dieta/uso terapêutico , Modelos Animais de Doenças , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/antagonistas & inibidores , Síndrome do Ovário Policístico/dietoterapia , Progesterona Redutase/antagonistas & inibidores , Regiões Promotoras Genéticas , Córtex Suprarrenal/enzimologia , Córtex Suprarrenal/metabolismo , Glândulas Suprarrenais/enzimologia , Glândulas Suprarrenais/metabolismo , Androgênios/análise , Androgênios/química , Androgênios/metabolismo , Animais , Linhagem Celular , AMP Cíclico/antagonistas & inibidores , AMP Cíclico/metabolismo , Ácidos Decanoicos/metabolismo , Gorduras na Dieta/metabolismo , Repressão Enzimática , Feminino , Humanos , Hiperandrogenismo/etiologia , Hiperandrogenismo/prevenção & controle , Resistência à Insulina , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/genética , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/metabolismo , Ovário/enzimologia , Ovário/metabolismo , Síndrome do Ovário Policístico/metabolismo , Síndrome do Ovário Policístico/patologia , Síndrome do Ovário Policístico/fisiopatologia , Progesterona Redutase/genética , Progesterona Redutase/metabolismo , Distribuição Aleatória , Ratos Wistar
13.
Brain ; 139(Pt 2): 431-43, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26608744

RESUMO

The medium chain triglyceride ketogenic diet is an established treatment for drug-resistant epilepsy that increases plasma levels of decanoic acid and ketones. Recently, decanoic acid has been shown to provide seizure control in vivo, yet its mechanism of action remains unclear. Here we show that decanoic acid, but not the ketones ß-hydroxybutryate or acetone, shows antiseizure activity in two acute ex vivo rat hippocampal slice models of epileptiform activity. To search for a mechanism of decanoic acid, we show it has a strong inhibitory effect on excitatory, but not inhibitory, neurotransmission in hippocampal slices. Using heterologous expression of excitatory ionotropic glutamate receptor AMPA subunits in Xenopus oocytes, we show that this effect is through direct AMPA receptor inhibition, a target shared by a recently introduced epilepsy treatment perampanel. Decanoic acid acts as a non-competitive antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects. This inhibitory effect is likely to be caused by binding to sites on the M3 helix of the AMPA-GluA2 transmembrane domain; independent from the binding site of perampanel. Together our results indicate that the direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anti-convulsant effect of the medium chain triglyceride ketogenic diet.


Assuntos
Ácidos Decanoicos/metabolismo , Ácidos Decanoicos/uso terapêutico , Receptores de AMPA/antagonistas & inibidores , Receptores de AMPA/metabolismo , Convulsões/tratamento farmacológico , Convulsões/metabolismo , Animais , Ácidos Decanoicos/farmacologia , Feminino , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Masculino , Técnicas de Cultura de Órgãos , Ligação Proteica/fisiologia , Estrutura Secundária de Proteína , Ratos , Ratos Sprague-Dawley , Receptores de AMPA/química , Xenopus laevis
14.
J Food Sci ; 80(8): H1912-7, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26130050

RESUMO

The total and positional fatty acid composition in camphor tree (Cinnamomum camphora) seed kernel oil (CKO) were analyzed, and for the first time, the effect of CKO on body fat deposition and blood lipids in rats was studied. The major fatty acids in CKO were determined to be decanoic acid (C10:0, 51.49%) and dodecanoic acid (C12:0, 40.08%), and uniformly distributed at Sn-1, 3, and Sn-2 positions in triglyceride (TG). Rats were randomly divided into control, CKO, lard, and soybean oil groups. At the end of the experiment, levels of blood lipids and the fats of abdomen in the rats were measured. The main organ were weighted and used for the histological examination. The results showed that body weight and fat deposition in CKO group were significantly lower than the lard and soybean groups. Moderate consumption of CKO was found to improve the levels of blood TG and low density lipoprotein cholesterol.


Assuntos
Gordura Abdominal/metabolismo , Peso Corporal/efeitos dos fármacos , Cinnamomum camphora/química , Ácidos Decanoicos/farmacologia , Ácidos Láuricos/farmacologia , Lipídeos/sangue , Óleos de Plantas/farmacologia , Animais , LDL-Colesterol/sangue , Ácidos Decanoicos/uso terapêutico , Gorduras na Dieta/farmacologia , Hiperlipidemias/metabolismo , Hiperlipidemias/prevenção & controle , Hipolipemiantes/farmacologia , Hipolipemiantes/uso terapêutico , Ácidos Láuricos/uso terapêutico , Masculino , Obesidade/metabolismo , Obesidade/prevenção & controle , Óleos de Plantas/química , Óleos de Plantas/uso terapêutico , Ratos Sprague-Dawley , Sementes/química , Óleo de Soja/farmacologia , Óleo de Soja/uso terapêutico , Árvores , Triglicerídeos/sangue
15.
No Shinkei Geka ; 43(7): 603-10, 2015 Jul.
Artigo em Japonês | MEDLINE | ID: mdl-26136324

RESUMO

BACKGROUND: In Japan, patients with malignant glioma have been treated with BCNU wafers (Gliadel®) since January 2013. Several adverse events(AEs)associated with implantation of BCNU wafers, including cerebral edema or cyst formation, are recognized. Here, we report a retrospective review of the experience with implantation of BCNU wafers in our institutions and our findings regarding the risk factors for the AEs. METHODS: We reviewed the records of patients with malignant glioma who were implanted with BCNU wafers between April 2013 and September 2014. Their AEs were examined clinically and radiologically and evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) grading. For investigating the association between risk factors and incidence of AEs, histological diagnosis, extent of resection, and period of BCNU wafers implantation surgery were selected as possible risk factors. RESULTS: Twenty-one patients were included in this investigation. There were no associations among incidence of AEs and histological diagnosis or extent of tumor resection. However, regarding the period of BCNU wafers implantation, additional resection for newly diagnosed tumors and resection for recurrent tumors tended to increase the rate and severity of AEs, especially cerebral edema, compared to primary resection. CONCLUSION: In cases of BCNU wafers implantation, the incidence and degree of AEs might increase if additional resection for newly diagnosed tumors or resection for recurrent tumors is performed. Our investigation revealed that AEs associated with implantation of BCNU wafers tend to occur in the repeated glioma surgery.


Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Carmustina/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Glioma/tratamento farmacológico , Poliésteres/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/efeitos adversos , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/cirurgia , Carmustina/administração & dosagem , Carmustina/efeitos adversos , Terapia Combinada , Ácidos Decanoicos/administração & dosagem , Ácidos Decanoicos/efeitos adversos , Progressão da Doença , Feminino , Glioma/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Poliésteres/administração & dosagem , Poliésteres/efeitos adversos , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento
16.
Med Mycol J ; 56(1): J23-9, 2015.
Artigo em Japonês | MEDLINE | ID: mdl-25855024

RESUMO

A daily eatable candy that has possible protective activity against oral candidiasis was experimentally produced. The candy was made from reduced-maltose as main constituent and from several natural products, such as oligonol (depolymerized polyphenols derived from lychee), cinnamon (cassia), citral, and capric acid, which are known to have anti-Candida activity in vitro and in vivo. The candy effectively inhibited the mycelial growth of C. albicans, even when it was diluted 1,000 times with culture media. We assessed the protective activity of the candy against murine candidiasis. When 50µl of candy dissolved and diluted 4 times with water was administered 3 times into the oral cavity of Candida infected mice, the score of lesions on the Candida-infected tongues improved on day 2. These findings suggest that this candy has potential as food that provides protective activity against oral candidiasis.


Assuntos
Candidíase Bucal/tratamento farmacológico , Candidíase Bucal/microbiologia , Doces , Cassia/química , Catequina/análogos & derivados , Ácidos Decanoicos/farmacologia , Monoterpenos/farmacologia , Fenóis/farmacologia , Extratos Vegetais/farmacologia , Polifenóis/farmacologia , Monoterpenos Acíclicos , Animais , Candida albicans/efeitos dos fármacos , Candida albicans/isolamento & purificação , Candidíase Bucal/prevenção & controle , Catequina/farmacologia , Catequina/uso terapêutico , Codonopsis/química , Ácidos Decanoicos/uso terapêutico , Modelos Animais de Doenças , Combinação de Medicamentos , Farmacorresistência Fúngica , Ácidos Graxos/farmacologia , Ácidos Graxos/uso terapêutico , Glycyrrhiza/química , Maltose/análogos & derivados , Camundongos , Camundongos Endogâmicos ICR , Monoterpenos/uso terapêutico , Fenóis/uso terapêutico , Extratos Vegetais/uso terapêutico , Polifenóis/uso terapêutico , Própole , Organismos Livres de Patógenos Específicos , Amido , Álcoois Açúcares , Resultado do Tratamento
17.
Int J Mol Sci ; 16(3): 5014-27, 2015 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-25749477

RESUMO

Colorectal cancer, breast cancer and skin cancer are commonly-reported cancer types in the U.S. Although radiation and chemotherapy are routinely used to treat cancer, they produce side effects in patients. Additionally, resistance to chemotherapeutic drugs has been noticed in cancers. Thus, there is a need for effective and safe bioprophylactics and biotherapeutics in cancer therapy. The medicinal value of goat milk has been recognized for centuries and is primarily attributed to three fatty acids, namely capric, caprylic and caproic acids. This research investigates the anticancer property of these fatty acids on human colorectal, skin and mammary gland cancer cells. The cancer cells were treated with various concentrations of fatty acids for 48 h, and cell viability was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Additionally, real-time quantitative PCR (RT-qPCR) was performed to elucidate the potential anti-cancer mechanisms of the three fatty acids under investigation. Capric, caprylic and caproic acids reduced cancer cell viability by 70% to 90% (p < 0.05) compared to controls. RT-qPCR data indicated that these natural molecules produced anticancer effects by down-regulating cell cycle regulatory genes and up-regulating genes involved in apoptosis. Future research will validate the anticancer effect of these fatty acids in an appropriate in vivo model.


Assuntos
Antineoplásicos/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Animais , Antineoplásicos/química , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Caproatos/química , Caproatos/farmacologia , Caproatos/uso terapêutico , Caprilatos/química , Caprilatos/farmacologia , Caprilatos/uso terapêutico , Caspase 8/metabolismo , Proteínas de Ciclo Celular/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Ácidos Decanoicos/química , Ácidos Decanoicos/farmacologia , Ácidos Decanoicos/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Feminino , Cabras , Células HCT116 , Humanos , Leite/metabolismo , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/metabolismo , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/metabolismo , Neoplasias Cutâneas/patologia , Regulação para Cima/efeitos dos fármacos
18.
J Neurooncol ; 122(2): 367-82, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25630625

RESUMO

Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma. Widespread use has been limited for several reasons, including concern that their use may preclude enrollment in subsequent clinical trials due to uncertainty about confounding of results and potential toxicities. This meta-analysis estimated survival following treatment with CW for HGG. A literature search identified relevant studies. Overall survival (OS), median survival, and adverse events (AEs) were summarized. Analysis of variance evaluated effects of treatment (CW vs non-CW) and diagnosis (new vs recurrent) on median survival. The analysis included 62 publications, which reported data for 60 studies (CW: n = 3,162; non-CW: n = 1,736). For newly-diagnosed HGG, 1-year OS was 67 % with CW and 48 % without; 2-year OS was 26 and 15 %, respectively; median survival was 16.4 ± 21.6 months and 13.1 ± 29.9 months, respectively. For recurrent HGG, 1-year OS was 37 % with CW and 34 % without; 2-year OS was 15 and 12 %, respectively; median survival was 9.7 ± 20.9 months and 8.6 ± 22.6 months, respectively. Effects of treatment (longer median survival with CW than without; P = 0.043) and diagnosis (longer median survival for newly-diagnosed HGG than recurrent; P < 0.001) on median survival were significant, with no significant treatment-by-diagnosis interaction (P = 0.620). The most common AE associated with wafer removal was surgical site infection (SSI); the most common AEs for repeat surgery were mass effect, SSI, hydrocephalus, cysts in resection cavity, acute hematoma, wound healing complications, and brain necrosis. These data may be useful in the context of utilizing CW in HGG management, and in designing future clinical trials to allow CW-treated patients to participate in experimental protocols.


Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Carmustina/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Glioma/tratamento farmacológico , Poliésteres/uso terapêutico , Antineoplásicos Alquilantes/efeitos adversos , Neoplasias Encefálicas/patologia , Carmustina/efeitos adversos , Ácidos Decanoicos/efeitos adversos , Implantes de Medicamento/efeitos adversos , Implantes de Medicamento/uso terapêutico , Glioma/patologia , Humanos , Gradação de Tumores , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/patologia , Poliésteres/efeitos adversos , Análise de Sobrevida , Resultado do Tratamento
19.
Artigo em Inglês | MEDLINE | ID: mdl-25445478

RESUMO

Capric acid (CA10) is a 10-carbon medium-chain fatty acid abundant in the medium-chain triglyceride ketogenic diet (MCT KD). The purpose of this study was to characterize acute anticonvulsant effects of CA10 across several seizure tests in mice. Anticonvulsant effects of orally (p.o.) administered CA10 were assessed in the maximal electroshock seizure threshold (MEST), 6-Hz seizure threshold, and intravenous pentylenetetrazole (i.v. PTZ) seizure tests in mice. Acute effects of CA10 on motor coordination were assessed in the grip and chimney tests. Plasma and brain concentrations of CA10 were measured. Co-administration studies with CA10 and another abundant medium-chain fatty acid, caprylic acid (CA8) were performed. CA10 showed significant and dose-dependent anticonvulsant properties by increasing seizure thresholds in the 6-Hz and MEST seizure tests; it was ineffective in the i.v. PTZ seizure test. At higher doses than those effective in the 6-Hz and MEST seizure tests, CA10 impaired motor performance in the grip and chimney tests. An enhanced anticonvulsant response in the 6-Hz seizure test was produced when CA8 and CA10 were co-administered. An acute p.o. administration of CA10 resulted in dose-proportional increases in its plasma and brain concentrations. CA10 exerted acute anticonvulsant effects at doses that produce plasma exposures comparable to those reported in epileptic patients on the MCT KD. An enhanced anticonvulsant effect is observed when CA10 and the other main constituent of the MCT KD, CA8, were co-administered. Thus, acute anticonvulsant properties of CA10 and CA8 may influence the overall clinical efficacy of the MCT KD.


Assuntos
Anticonvulsivantes/uso terapêutico , Caprilatos/uso terapêutico , Ácidos Decanoicos/uso terapêutico , Convulsões/tratamento farmacológico , Ácido 3-Hidroxibutírico/sangue , Animais , Anticonvulsivantes/farmacocinética , Glicemia/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Ácidos Decanoicos/farmacocinética , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Quimioterapia Combinada , Concentração de Íons de Hidrogênio/efeitos dos fármacos , Masculino , Camundongos , Destreza Motora/efeitos dos fármacos , Convulsões/sangue
20.
J Neurol Sci ; 343(1-2): 60-5, 2014 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-24874252

RESUMO

OBJECTIVES: Malignant gliomas are common primary brain tumors with dismal prognosis. The blood-brain barrier and unacceptable systemic toxicity limit the employment of chemotherapeutic agents. BCNU-impregnated biodegradable polymers (Gliadel®) have been demonstrated to prolong the survival of patients with malignant gliomas. Until now, no biodegradable drug delivery system has been commercially available in China. In the present study, we evaluated the safety of implants with high-dose BCNU in Chinese patients with recurrent malignant gliomas. PATIENTS AND METHODS: Adults with supratentorial recurrent malignant glioma were eligible. High-dose BCNU-loaded PLGA implants (20mg of BCNU in each implant) were placed in the debulking cavity. The implants were investigated by a classical 3+3 design. Four levels of BCNU, up to 12 implants, were evaluated. Pharmacokinetic sampling was performed. The toxicity of the implants and the survival of patients were recorded. RESULTS: Fifteen recurrent patients were enrolled with 12 glioblastomas and 3 anaplastic gliomas. Among 15 patients, 3 were treated with 3 implants (60 mg of BCNU), 3 with 6 implants (120 mg), 3 with 9 implants (180 mg) and 6 with 12 implants (240 mg). No dose-limiting toxicity was observed in the cohort of patients. Subgaleal effusion was the most common adverse event, presenting in 7 patients (46.7%). The median overall survival (OS) was 322 days (95% CI, 173-471 days). The 6-month, 1-year and 2-year survival rates were 66.7%, 40% and 13.3%, respectively. CONCLUSIONS: The high-dose BCNU-loaded PLGA implants were safe for Chinese patients with recurrent malignant gliomas and further investigation for efficacy is warranted.


Assuntos
Implantes Absorvíveis , Antineoplásicos Alquilantes/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Carmustina/uso terapêutico , Glioma/tratamento farmacológico , Adolescente , Adulto , Idoso , Antineoplásicos Alquilantes/farmacocinética , Povo Asiático , Carmustina/farmacocinética , Ácidos Decanoicos/uso terapêutico , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Glioma/patologia , Humanos , Avaliação de Estado de Karnofsky , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/tratamento farmacológico , Poliésteres/uso terapêutico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...